Implantable delivery vehicle for ocular delivery of muscarinic antagonists
The present invention provides compositions and methods for treating ocular disorders such as myopia.
1. A method of treating high myopia in an individual having high myopia, the method comprising administering to the individual an effective amount of a muscarinic antagonist-containing biodegradable hydrogel, wherein the hydrogel is selected from the groups consisting of a bifunctional block copolymer of poly(ethylene oxide) (PEO) and poly(propylene oxide) (PPO), a poly(N-isopropylacrylamide)-based hydrogel, or a poly(N-isopropylacrylamide)-acrylic acid copolymer, and poly(2-hydroxyethylene methacrylate), wherein the muscarinic antagonist-containing hydrogel is administered by intraorbital injection.
2. The method of claim 1 , wherein the hydrogel is a bifunctional block copolymer of PEO and PPO.
3. The method of claim 1 , wherein the hydrogel is a poly(N-isopropylacrylamide)-based hydrogel.
4. The method of claim 3 , wherein the hydrogel is a poly(N-isopropylacrylamide)-acrylic acid copolymer.
5. The method of claim 1 , wherein the hydrogel is comprises poly(2-hydroxyethylene methacrylate).
6. The method of claim 1 , wherein the hydrogel comprises poly(vinyl pyrrolidone).
7. The method of claim 1 , wherein the muscarinic antagonist is encapsulated in a nanoparticle or a microparticle.
8. The method of claim 7 , wherein the nanoparticle comprises a hydrophobic polymer and a hydrophilic polymer, wherein the hydrophobic polymer forms a hydrophobic core.
9. The method of claim 8 , wherein the hydrophilic polymer is a poly(ethylene glycol) polymer.
10. The method of claim 8 , wherein the hydrophobic polymer is poly(L-lactide).
11. The method of claim 7 , wherein the muscarinic antagonist is not linked to a nanoparticle polymer.
12. The method of claim 1 , wherein the hydrogel comprises poly(N-isopropylacrylamide-co-acrylic acid).
13. The method of claim 1 , wherein the muscarinic antagonist is atropine.
14. The method of claim 1 , wherein the muscarinic antagonist is pirenzepine.
15. The method of claim 1 , wherein the muscarinic antagonist is a combination of atropine and scopolamine.
16. The method of claim 1 , wherein the muscarinic antagonist is a 1-[cycloalkylpiperidin-4-yl]-2H benzimidazolone.
17. The method of claim 1 , wherein the muscarinic antagonist is telenzepine.
18. The method of claim 1 , wherein the muscarinic antagonist-containing hydrogel is administered via intraorbital injection at the posterior pole.
19. The method of claim 1 , wherein the muscarinic antagonist-containing hydrogel is administered via sub-Tenon's injection at the posterior pole.
20. The method of claim 1 , wherein the individual is a human.